RhumbLine Advisers’s Benitec Biopharma BNTC Stock Holding History

RhumbLine Advisers’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$218K	Buy	20,445 +2,777	+16%	+$32.2K	﹤0.01%	3081
2025 Q4	$238K	Sell	17,668 -2,856	-14%	-$39.5K	﹤0.01%	3096
2025 Q3	$288K	Sell	20,524 -334	-2%	-$4.26K	﹤0.01%	3025
2025 Q2	$244K	Buy	20,858 +20,672	+11,114%	+$289K	﹤0.01%	3119
2025 Q1	$2.42K	Hold	186	–	–	﹤0.01%	3968
2024 Q4	$2.35K	Hold	186	–	–	﹤0.01%	4026
2024 Q3	$1.71K	Hold	186	–	–	﹤0.01%	4066
2024 Q2	$1.3K	Hold	186	–	–	﹤0.01%	4217
2024 Q1	$952	Hold	186	–	–	﹤0.01%	4149
2023 Q4	$602	Hold	186	–	–	﹤0.01%	4194
2023 Q3	$561	Hold	186	–	–	﹤0.01%	4224
2023 Q2	$752	Buy	+186	New	+$709	﹤0.01%	4297

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RhumbLine Advisers's BNTC Position: Q1 2026 in Review

RhumbLine Advisers increased its Benitec Biopharma (BNTC) stake by 16% in Q1 2026, buying an estimated $32.2K and bringing the position to 20,445 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #3081.

RhumbLine Advisers first reported a position in BNTC in Q2 2023 and has held it in 12 quarters since. The position peaked at $288K in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

RhumbLine Advisers held 20,445 shares of Benitec Biopharma worth $218K as of Q1 2026.
RhumbLine Advisers bought 2,777 Benitec Biopharma shares in Q1 2026, an estimated $32.2K.
Benitec Biopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3081 holding.
RhumbLine Advisers first reported a position in Benitec Biopharma in Q2 2023 and has held it in 12 quarters since.
RhumbLine Advisers's Benitec Biopharma position peaked at $288K in Q3 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.